ANNOUNCEMENT 09 Oct 2020

On 9 October 2020, the U.S. Administration awarded $430 million to AstraZeneca for the late-stage development and large-scale manufacturing of COVID-19 therapeutic.

 

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

U.S. Medical Countermeasures, Newsroom, “Trump Administration expands collaboration with AstraZeneca to develop and manufacture an investigational monoclonal antibody to prevent COVID-19”. Available at: https://www.medicalcountermeasures.gov/newsroom/2020/astrazeneca2/

Inception date: 09 Oct 2020 | Removal date: open ended

Financial grant

On 9 October 2020, as part of the operation warp speed goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense announced awarding USD 486 million to AstraZeneca for the late-stage development and large-scale manufacturing of monoclonal antibody combination therapy that can be used for the treatment and protection against COVID-19.

Concerning the collaboration with AstraZeneca, HHS Secretary Alex Azar said: “In addition to Operation Warp Speed’s historic progress on vaccines, we are supporting promising monoclonal antibodies for prevention and treatment all the way through to supply, allowing faster distribution if trials are successful. The more good news about COVID-19 treatments is constantly emerging, and President Trump’s commitment to supporting life-saving measures, like AstraZeneca’s antibody candidate which may help deliver these products to our nation’s most vulnerable populations.”

Operation Warp Speed is a partnership among components of the Department of Health and Human Services and the Department of Defense, engaging with private firms and other federal agencies, and coordinating among existing HHS-wide efforts to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

Previously, US Administration awarded 23.7 million to AstraZeneca to support the company’s development of a monoclonal antibody combination product against SARS-CoV-2 (see related state act). 

It is announced that on 8 March 2021, AstraZeneca signed a USD205 million agreement with the U.S. government to provide Covid-19 antibody treatment. 

 

 

AFFECTED SECTORS